1、智慧芽LS-GTM1目录重点创新药数据梳理02具有立项价值的热门药物03智慧芽数据库加速医药情报收集042025 JPM 主要数据回顾01JPM总结和2025展望052Alnylam 2025 Goals3Alnylam:Nucresiran Offers Potential for Best-in-Class Profile4Alnylam:Next Wave of Multi-Billion-Dollar Opportunities5AMGEN:OLPASIRAN BEST-IN-CLASS MOLECULE TARGETING Lp(a)6药物靶点药物类型适应症原研机构临床阶段Lepod

2、isiranLp(a)siRNA动脉粥样硬化|低脂蛋白血症|脂蛋白类型-Lp系统Lp（A）高脂蛋白血症Dicerna Pharmaceuticals,Inc.临床3期OlpasiranLp(a)siRNA动脉粥样硬化Arrowhead Pharmaceuticals,Inc.临床3期PelacarsenLp(a)ASO动脉粥样硬化|脂蛋白(a)高脂蛋白血症|心血管疾病|主动脉瓣狭窄Ionis Pharmaceuticals,Inc.临床3期CER-001APOA1 x Phospholipids重组蛋白脓毒症|急性冠状动脉综合征|动脉粥样硬化|脂质代谢紊乱|新型冠状病毒感染|肾功能不全Cere

3、nis Therapeutics,Inc.临床2期MuvalaplinLp(a)小分子化药动脉粥样硬化|心血管疾病|高脂蛋白血症|低脂蛋白血症Eli Lilly&Co.临床2期ZerlasiranLp(a)siRNA动脉粥样硬化|心血管疾病|高脂蛋白血症Silence Therapeutics Plc临床2期Kylo-11Lp(a)siRNA动脉粥样硬化|脂蛋白(a)高脂蛋白血症厦门甘宝利生物医药临床1期YS-2302018Lp(a)小分子化药心血管疾病石药临床前靶向Lp(a)的临床在研药物信息7参考：新药情报库，链接：https:/ ANTICIPATED IN 20258Blueprint

4、:Accelerate and expand development of BLU-8089Blueprint:BLU-808 designed to be a BIC oral,once-daily wtKIT inhibitor10Blueprint:Single ascending dose(SAD)11Blueprint:Multiple ascending dose(MAD)12Blueprint:BLU-808 has a tunable profile for optimizing benefit-risk13Blueprint:BLU-808 WO2024118887A114B

5、lueprint:Highly productive research engine has nominated 17 candidates15BMS:Admilparant(LPA1 antagonist)16药物靶点药物类型适应症原研机构临床阶段AdmilparantLPAR1小分子化药进行性纤维化间质性肺病|特发性肺纤维化Bristol Myers Squibb Co.临床3期FipaxalparantLPAR1小分子化药弥漫性硬皮病|特发性肺纤维化Amgen,Inc.|Sanofi临床2期LTSE-2578LPAR1小分子化药特发性肺纤维化硕迪生物临床1期PIPE-791LPAR1小分

6、子化药慢性进行性多发性硬化|原发性进行性多发性硬化|继发进展型多发性硬化|特发性肺纤维化|多发性硬化症|慢性疼痛|腰痛|骨关节炎|神经炎症Contineum Therapeutics,Inc.临床1期ACT-1016-0707LPAR1小分子化药纤维化Idorsia Pharmaceuticals Ltd.临床前AMS-III-1086LPAR1小分子化药先天性肝纤维化Sungkyunkwan University临床前BMS-986234LPAR1小分子化药特发性肺纤维化Bristol Myers Squibb Co.临床前CTX-343(Contineum Therapeutics)LPA